The schizophrenia market is projected to increase from $6.4bn in 2015 to $7.3bn by 2025 at a compound annual growth rate of 1.4%, according to a report by GlobalData.

Titled 'PharmaPoint: Schizophrenia – Global Drug Forecast and Market Analysis to 2025', the report covers the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan.

Growth in the schizophrenia market is expected to be driven mainly by late-stage pipeline products designed to address unmet needs and development of long-acting injectable (LAI) formulations.

The treatment of negative symptoms characterised as absence of normal emotional responses such as apathy or asociality is a major unmet need in the schizophrenia market.

"The treatment of negative symptoms characterised as absence of normal emotional responses such as apathy or asociality is a major unmet need in the schizophrenia market."

Negative symptoms have a far great impact on the quality of life of a patient and a new drug that addresses these symptoms is, therefore, needed. No drug is available in the market currently to treat these symptoms.

Two late-stage pipeline products under development to treat the negative symptoms include Minerva’s MIN-101 and Intra-Cellular Therapies’ ITI-007. If proven effective, these products are expected to drive growth in the schizophrenia market.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

GlobalData analyst Christos Michaelides opines that drugs targeting negative symptoms present significant opportunities for pharmaceutical companies by 2025.

Considerable R&D risk, however, is involved in the development of the drugs as many fail in clinical trials due to lack of efficacy.